文献速递泌尿系结石

氨甲环酸对复杂肾结石经皮肾镜取石术患者输血率的影响:随机双盲安慰剂对照试验

Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
PubMed 文献 · BJU Int · 2021-06-13

该随机双盲安慰剂对照试验纳入192例Guy结石评分III-IV级的复杂肾结石行PCNL患者,麻醉诱导时单次给予氨甲环酸1g或安慰剂。结果显示氨甲环酸组围手术期输血率显著降低(2.2% vs 10.4%),即刻及3个月无石率更高,血红蛋白恢复更快,且不增加并发症。

要点

  • 复杂肾结石行PCNL时,麻醉诱导期单次氨甲环酸1g可显著降低输血风险。
  • 氨甲环酸组即刻和3个月无石率均更高,血红蛋白恢复更快。
  • 两组手术时间和并发症无统计学差异,安全性良好。

核心结论

  • 复杂肾结石行PCNL患者麻醉诱导时单次给予氨甲环酸安全,可将输血需求降低约五倍。
  • 氨甲环酸可能有助于提高结石清除率并加快血红蛋白恢复,且不增加并发症。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,前瞻性纳入192例Guy结石评分III-IV级的复杂肾结石行PCNL患者,按1:1随机分组。
  • 氨甲环酸组在麻醉诱导时接受单次氨甲环酸1g,对照组接受安慰剂。
  • 主要结局为围手术期输血发生率,次要结局包括失血量、手术时间、无石率和并发症。

主要发现

  • 氨甲环酸组总体输血风险降低(2.2% vs 10.4%;相对风险0.21,95%CI 0.03-0.76,P=0.033;需治疗人数12)。
  • 氨甲环酸组即刻无石率高于安慰剂组(29% vs 14.7%,OR 2.37,95%CI 1.15-4.87,P=0.019)。
  • 氨甲环酸组3个月无石率高于安慰剂组(46.2% vs 28.1%,OR 2.20,95%CI 1.20-4.02,P=0.011)。
  • 氨甲环酸组血红蛋白恢复更快(平均21.3天,P=0.001)。
  • 两组手术时间和并发症无统计学差异。

关键数值与推荐

  • 复杂肾结石定义为Guy结石评分III-IV级。
  • 氨甲环酸用法为麻醉诱导时单次1g。
  • 主要结局输血率:氨甲环酸组2.2%,安慰剂组10.4%,相对风险0.21(95%CI 0.03-0.76,P=0.033)。
  • 无石率:即刻29% vs 14.7%(OR 2.37,95%CI 1.15-4.87,P=0.019);3个月46.2% vs 28.1%(OR 2.20,95%CI 1.20-4.02,P=0.011)。

临床怎么用

  • 对于Guy结石评分III-IV级复杂肾结石行PCNL的患者,可考虑在麻醉诱导时单次给予氨甲环酸1g作为标准临床实践。
  • 该干预可降低围手术期输血需求,并可能改善结石清除和血红蛋白恢复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the efficacy and safety of single-dose tranexamic acid on the blood transfusion rate and outcomes of patients with complex kidney stones undergoing percutaneous nephrolithotomy (PCNL). PATIENTS AND METHODS: In a randomised, double-blinded, placebo-controlled trial, 192 patients with complex kidney stone (Guy's Stone Scores III-IV) were prospectively enrolled and randomised (1:1 ratio) to receive either one dose of tranexamic acid (1 g) or a placebo at the time of anaesthetic induction for PCNL. The primary outcome measure was the occurrence rate of perioperative blood transfusion. The secondary outcome measures included blood loss, operative time, stone-free rate (SFR), and complications. ClinicalTrials.gov identifier: NCT02966236. RESULTS: The overall risk of receiving a blood transfusion was reduced in the tranexamic acid group (2.2% vs 10.4%; relative risk, 0.21, 95% confidence interval [CI] 0.03-0.76, P = 0.033; number-needed-to-treat: 12). Patients randomised to the tranexamic acid group had a higher immediate and 3-month SFR compared with those in the placebo group (29% vs 14.7%, odds ratio [OR] 2.37, 95% CI 1.15-4.87, P = 0.019, and 46.2% vs 28.1%, OR 2.20, 95% CI 1.20-4.02, P = 0.011, respectively). Faster haemoglobin recovery occurred in patients in the tranexamic acid group (mean, 21.3 days; P = 0.001). No statistical differences were found in operative time and complications between groups. CONCLUSIONS: Tranexamic acid administration is safe and reduces the need for blood transfusion by five-times in patients with complex kidney stones undergoing PCNL. Moreover, tranexamic acid may contribute to better stone clearance rate and faster haemoglobin recovery without increasing complications. A single dose of tranexamic acid at the time of anaesthetic induction could be considered standard clinical practice for patients with complex kidney stones undergoing PCNL.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Batagello CA, Vicentini FC, Monga M, et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial. BJU Int. 2021. PMID: 33630393. doi:10.1111/bju.15378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。